10-Q · May 15, 2026
Marker Therapeutics reported revenues of $1 million for Q1 2026, matching revenue expectations but reflecting a decline from prior quarters. The company improved its EPS loss to $0.04 from $0.12 in the previous quarter,…
Earnings analysis · 10-Q
MRKR earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q provides no current-period income statement, balance sheet, cash flow, segment, or quantitative outlook data, so revenue, margins, EPS, liquidity, and free cash flow cannot be assessed from the filing…
Read full summary
The extracted 10-Q provides no current-period income statement, balance sheet, cash flow, segment, or quantitative outlook data, so revenue, margins, EPS, liquidity, and free cash flow cannot be assessed from the filing content supplied. Management reported effective disclosure controls as of June 30, 2026, no material control changes, no material legal proceedings, and 0 unregistered securities issuances. Risk factors were unchanged from the 2025 Form 10-K filed March 18, 2026, while no numeric guidance was provided.
What stood out
-
Effective Disclosure Controls
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, although the filing notes that controls provide reasonable—not absolute—assurance.
-
No Control Changes
There were no changes during the fiscal quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
No Material Legal Proceedings
The company reported no pending or threatened legal proceedings believed likely to have a material adverse effect on its business, operating results, or financial condition as of August 14, 2026.
-
No Unregistered Issuances
The company recorded 0 issuances of unregistered securities during the three months ended June 30, 2026, limiting evidence of equity financing in the quarter.
-
No Insider Trading Plans
No director or officer adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the quarter ended June 30, 2026.
-
Recent Charter Amendment
The filing includes Certificate of Amendment exhibit 3.1.3, filed May 4, 2026, indicating a recent corporate charter amendment.
What to watch
-
Existing Risks Remain Unchanged
The filing states there have been no material changes to the risk factors in the 2025 Form 10-K filed March 18, 2026; therefore, the previously disclosed risks remain applicable without new mitigation detail.
-
Residual Control Risk
Management cautions that internal controls cannot prevent or detect all errors and fraud and provide only reasonable assurance, creating residual reporting-control risk as of June 30, 2026.
-
Limited Financial Visibility
The filing does not provide current-period cash, debt, operating cash flow, free cash flow, revenue, margin, or segment data in the extracted sections, limiting assessment of liquidity and operating performance for the quarter ended June 30, 2026.
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q. The filing does not include an updated numeric guidance discussion.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.